<DOC>
	<DOCNO>NCT02335099</DOCNO>
	<brief_summary>This study randomize , placebo-controlled , single blind clinical trial . Seventy patient ESRD chronic HD function AVF recruit . The following data document patient : 1-Age/gender/race/body weight/cause ESRD 2-Vintage HD 3-Time since access place 4-Type place access blood flow rate access 5-History prior access problem 6-Comorbid condition ( Hypertension , coronary artery disease , Diabetes Mellitus , Bleeding problem , peripheral vascular disease ) . 7-Current medication ( Coumadin , Erythropoiesis stimulate agent , heparin , antiplatelets , digoxin , statin ) . Patients randomize two group receive : Group 1 : Ticagrelor 90 mg PO BID Group 2 : Placebo drug PO BID .</brief_summary>
	<brief_title>Determine Safety/Efficacy Ticagrelor Maintaining Patency Arterio-Venous Fistulae Created Hemodialysis</brief_title>
	<detailed_description>This study randomize , placebo-controlled , single blind clinical trial . Seventy patient ESRD chronic HD function AVF recruit . Consent form obtain . History physical , dialysis parameter laboratory data ( CBC , CMP , PTT &amp; INR ) obtain throughout study . The following data document patient : 1-Age/gender/race/body weight/cause ESRD 2-Vintage HD 3-Time since access place 4-Type place access blood flow rate access 5-History prior access problem 6-Comorbid condition ( Hypertension , coronary artery disease , Diabetes Mellitus , Bleeding problem , peripheral vascular disease ) . 7-Current medication ( Coumadin , Erythropoiesis stimulate agent , heparin , antiplatelets , digoxin , statin ) . Patients randomize two group receive : Group 1 : Ticagrelor 90 mg PO BID Group 2 : Placebo drug PO BID . Subjects screen visit qualify study 18 additional visit . All visit occur subject normal dialysis treatment . Subjects randomize either Ticagrelor group placebo group . Subjects study medication 6 month follow period drug 6 month . Subjects see twice month study medication month follow period . While subject study medication study team assess side effect study medication put relation study drug study visit . The study team use clinical monitoring suggest Beathard ( 21 ) . The study team document subject 's adherence study , hospitalize caused hospitalization . A monthly intra-access flow obtain use ultrasound dilution transonics part standard care . Any change clinical assessment access , prolong bleeding ( &gt; 20 minute ) removal needle , trend decrease intra-access blood flow determine transonic ( &gt; 25 % original flow ) , access flow rate &lt; 400 ml/min , prompt referral fistulogram . If confirm stenosis ( &gt; 50 % stenosis access diameter ) intervention ( angioplasty ) perform . This intervention part subject standard care .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients chronic hemodialysis function arteriovenous fistula Recent history bleed last 3 month precede enrollment History bleeding disorder ( hemophilia , Von Willebrandt disease , etcâ€¦ . ) Recent history blood transfusion last 3 month precede enrollment Recent serious injury surgery last 3 month precede enrollment History gastrointestinal ulcer Moderatesevere hepatic impairment Uncontrolled blood pressure ( SBP &gt; 200 DBP &gt; 110 ) post dialysis History stroke Pregnant femalesself report Hypersensitivity Aspirin /antiplatelets Subjects use peroral anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>vascular access</keyword>
	<keyword>vascular access patency</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>brilinta</keyword>
</DOC>